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Summary
Although apolipoprotein E (APOE) variants are associated with
age-related diseases, the underlying mechanism is unknown and
DNA methylation may be a potential one. With methylation data,
measured by the Infinium Human Methylation 450 array, from
993 participants (age ranging from 18 to 87 years) in the Genetics
of Lipid Lowering Drugs and Diet Network (GOLDN) study, and
from Encyclopedia of DNA Elements (ENCODE) consortium,
combined with published methylation datasets, we described
the methylation pattern of 13 CpG sites within APOE locus, their
correlations with gene expression across cell types, and their
relationships with age, plasma lipids, and sequence variants.
Based on methylation levels and the genetic regions, we catego-
rized the 13 APOE CpG sites into three groups: Group 1 showed
hypermethylation (> 50%) and were located in the promoter
region, Group 2 exhibited hypomethylation (< 50%) and were
located in the first two exons and introns, and Group 3 showed
hypermethylation (> 50%) and were located in the exon 4. APOE
methylation was negatively correlated with gene expression
(minimum r = 0.66, P = 0.004). APOE methylation was signifi-
cantly associated with age (minimum P = 2.06E-08) and plasma
total cholesterol (minimum P = 3.53E-03). Finally, APOE methyl-
ation patterns differed across APOE e variants (minimum
P = 3.51E-05) and the promoter variant rs405509 (minimum
P = 0.01), which further showed a significant interaction with
age (P = 0.03). These findings suggest that methylation may be a
potential mechanistic explanation for APOE functions related to
aging and call for further molecular mechanistic studies.
Key words: apolipoprotein E; age; DNA methylation;
variants; epidemiology; interaction.
Introduction
Apolipoprotein E (ApoE, encoded by theAPOE gene), a protein involved in
both exogenous and endogenous lipid metabolism, plays a significant role
in the process of age-related diseases, including cardiovascular diseases,
Alzheimer’s disease, and age-related macular disease (Ang et al., 2008).
While the vast majority of studies have investigated relationships between
APOE sequence variants and age-related diseases (Davignon et al., 1988;
Saunders et al., 1996; Klaver et al., 1998; Ward et al., 2009), current
studies on the relationship between aging and methylation pattern APOE
are limited. One small-scale study suggested that the differences in APOE
methylation between brains with late-onset Alzheimer’s disease and
normal brains increasewithage (Wanget al., 2008). Theeffect of agingon
APOE methylation is highly plausible based on the general link between
DNA methylation and aging. For example, nearly every step of cellular
development and differentiation involves DNA methylation changes
(Cedar & Bergman, 2012). DNA methylation has also been shown to be
associated with age-related diseases (Johnson et al., 2012). Furthermore,
methylation of APOE was shown to be functional as it is modified by
environmental factors such as folate (Yi-Deng et al., 2007; Glier et al.,
2014) and correlates with clinical phenotypes in some (Turan et al., 2012)
but not all studies (Sharma et al., 2008).
In light of the potential shared relationship with aging that appears to
link APOE sequence variants and APOE methylation, along with the
observation that sequence variants may actually alter methylation status
(Zhi et al., 2013), we propose that studying the two phenomena in
combination may be especially informative. Specifically, three functional
single nucleotide polymorphisms (SNPs) may modify DNA methylation at
the APOE locus. The first SNP, rs405509, is located in the promoter
region. The variant of this SNP was postulated to increase DNA
methylation based on its demonstrated decreasing effect on gene
transcription (Artiga et al., 1998), the main functional effect of DNA
methylation (Lindahl, 1981). The other two SNPs are rs429358 and
rs7412, which define the e2/e3/e4 isoforms of ApoE and both are
located within exon 4. These two SNPs are hypothesized to change DNA
methylation as well, not only because they are located within the CpG
island contained in the exon 4, but also because both are CpG-related
SNPs (the cytosine allele forms a CpG dinucleotide while the thymine
allele disrupts it).
Using data from 993 participants of the Genetics of Lipid Lowering
Drugs and Diet Network (GOLDN) study, publically available data from
Encyclopedia of DNA Elements (ENCODE) consortium, and previously
open-published datasets, we described the general methylation pattern
of the 13 CpG sites distributed along the entire APOE locus, which were
available in the Infinium Human Methylation 450 array. With the data
from ENCODE consortium, we analyzed the relationship between APOE
methylation and gene expression across different cell types. Finally, we
utilized the GOLDN population to explore (i) whether age is associated
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with APOE methylation, (ii) whether the effects of age on APOE
methylation leads to changes in plasma lipids, the main functional
phenotype of APOE, and (iii) whether the effect of age on APOE
methylation can be modulated by methylation-related genetic variants in
the APOE locus.
Results
Population characteristics of GOLDN by age
Population characteristics were compared across age quintiles (Table 1).
Gender distribution did not differ across age quintiles. Compared to the
younger age quintiles, the older quintiles tended to contain fewer
smokers (P = 0.004) but more individuals with a past history of taking
antilipemic medications (P < 0.0001). Also, those individuals in the older
age quintiles tended to consume less total energy, vitamin B12, and
folate (P ≤ 0.0001).
APOE methylation patterns are similar in blood lymphocytes
and other cell types
We examined the methylation status of 13 CpG sites distributed along
the entire APOE using data from GOLDN, ENCODE, and previous
publications. The genetic structure of APOE locus is illustrated in Fig. 1A.
Based on both the methylation levels in GOLDN and genetic locations
(Fig. 1B), three groups of CpG sites can be distinguished. Specifically, the
first three CpG sites comprised a group (Group 1) that was both
hypermethylated (all sites > 50% methylation) and located within the
promoter region. The second group of CpG sites (Group 2, sites 4–9)
was both hypomethylated (all sites < 50%) and located in the 50 part of
the gene. The third group (Group 3, sites 10–13) was both hyperme-
thylated (all sites > 50%) and located at the 30 end of the gene. This
categorization of the 13 CpG sites into three groups was also suggested
by the heat map of GOLDN (Figure S1).
To explore the generalizability of the blood T lymphocyte used in
GOLDN, we compared the APOE methylation patterns of these 13 CpG
sites found in GOLDN (presented as the first bar in Fig. 1C) with those
measured across different cell types (presented as the bars starting from
the second in Fig. 1C), including primary cells from tissues of brain,
saliva, fat, muscle, and liver, and 61 cell lines from tissues of brain,
blood, breast, colon, epithelia, skin, muscle, heart, kidney, lung, ovary,
pancreas, blood vessel, and prostate (Table S1). In general, APOE
methylation patterns are similar across different cell types by consistently
showing that the methylation levels of the CpG sites within Group 2 are
lower than those of the sites located within Group 1 and Group 3.
Consistently, across all the cell types, CpG sites within Group 3 have
hypermethylation levels (all sites > 50%) and those sites in Group 2 have
hypomethylation levels (almost all sites < 50%). Methylation levels of the
CpG sites within Group 1 showed variation across cell types, which have
hypermethylation (> 50%) in tissues of brain and saliva, but hypome-
thylation (< 50%) in tissues of fat, muscle, and skin. Despite these
variations in Group 1, cell type-specific heat maps consistently suggested
that these 13 CpG sites can be categorized into three distinct groups
(Figures S2–S6).
APOE methylation patterns are correlated with APOE gene
expression
We extended our analyses in ENCODE by evaluating the relationship
between CpG methylation and gene expression across 17 cell types with
data available for both gene expression and methylation. Methylation of
four CpG sites, distributed across three methylation groups identified
above, was negatively correlated with gene expression (Table 2). Two
CpG sites within Group 1, CpG 2 (cg04406254) and CpG 3
(cg01032398), showed the strongest correlation with gene expression,
with Pearson’s correlation coefficients of 0.66 (P = 0.004) and 0.62
(P = 0.008), respectively. In Group 2, CpG 7 (cg18768621) had a
borderline significance (P = 0.05) with a coefficient of 0.48. In Group
3, CpG 12 (cg18799241) was negatively correlated with a coefficient of
0.51 (P = 0.04).
APOE methylation patterns are associated with age
We next evaluated relationships between age and APOE methylation by
examining methylation of the 13 CpG sites occurring within the three
distinct methylation groups (Group 1, Group 2, and Group 3), as
described above. Age was significantly associated with methylation of at
least one CpG site in each group (Table 3). For example, age was
significantly negatively associated with DNA methylation values for all
three CpG sites in Group 1 including CpG 1 (cg14123992), CpG 2
(cg04406254), and CpG 3 (cg01032398) (P = 8.00E-05, 2.06E-08, and
1.16E-04, respectively). However, age was significantly positively asso-
Table 1 Subject characteristics of GOLDN by age quintiles*
Variable
Age quintiles
P for trend†Q1 Q2 Q3 Q4 Q5
Age (year)‡ 24 (18–34) 40 (35–43) 47 (44–51) 57 (52–64) 71 (65–87) –
N 200 185 204 209 195 –
Men 88 (44.0) 98 (53.0) 96 (47.1) 99 (47.4) 94 (48.2) 0.64
Current smoker 17 (8.5) 18 (9.7) 21 (10.3) 13 (6.2) 4 (2.1) 0.004
Ever drinker 79 (39.5) 101 (54.6) 104 (51.0) 102 (48.8) 95 (48.7) 0.16
Total energy intake (kcal day1) 2448 (1758) 2228 (1202) 2169 (981) 2037 (925) 1746 (809) < 0.0001
Vitamin B12 intake (lg day1) 6.1 (4.4) 5.4 (3.3) 5.3 (3.0) 5.3 (2.9) 4.7 (3.3) 0.0001
Folate intake (lg day1) 467.0 (315.7) 411.9 (237.7) 398.2 (171.4) 398.5 (187.1) 362.9 (166.5) < 0.0001
History of taking antilipemic medications 0 (0.0) 2 (1.1) 1 (0.5) 14 (6.7) 20 (10.3) < 0.0001
*Data are means (standard deviation) or n (%).
†Mantel–Haenszel v2 tests and ANOVA tests were applied to obtain P-values for trend of categorical and continuous variables, respectively, according to the median of age
in each quintile.
‡Data are median age (minimum age–maximum age) within each quintile.
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ciated with methylation of CpG 8 (cg19514613) (P = 0.004), one CpG
site in Group 2. For Group 3, age was significantly negatively associated
with methylation of CpG 10 (cg16471933) (P = 0.04). Significant
relationships were not altered in the secondary analyses adjusted for
smoking, drinking, total energy intake, physical activity, vitamin B12
intake, folate intake, hormone replacement therapy in women, history of
taking antilipemic medications, and time of fasting blood drawn (data
not shown).
APOE methylation patterns may act as the intermediate
factors of the effects of age on blood lipids
We confirmed the known effects of age on plasma lipids in GOLDN
(Table 3) by showing that those individuals in the older age quintiles
tended to have higher total cholesterol (TC) (P = 1.04E-07), low-density
lipoprotein cholesterol (LDL-c) (P = 2.00E-04), high-density lipoprotein




Fig. 1 Gene structure and methylation pattern of APOE measured in blood T lymphocyte in GOLDN and other cell types in public datasets. Panel A shows the structure of
APOE gene. The arrow represents the direction of the gene, and filled rectangles represent exons. Panels B and C show the mean of APOEmethylation (%) for each of the 13
CpG sites measured in blood T lymphocytes in GOLDN and across different cell types in public datasets.
Age and genetic variants for APOE methylation, Y. Ma et al. 51
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
We also found that APOE methylation patterns are associated with
plasma lipids of TC and LDL-C, the main phenotypes of APOE (Table 4).
Methylations of six CpG sites from all three CpG groups were
significantly associated with plasma TC. Specifically, methylations of
CpG sites in Group 1 and Group 2, which were CpG 1 (cg14123992),
CpG 2 (cg04406254), CpG 10 (cg16471933), CpG 12 (cg18799241),
and CpG 13 (cg21879725), were negatively associated with TC
(P < 0.05). Methylation of the CpG site in Group 2, CpG 7
(cg18768621), was positively associated with TC (P = 0.02). For LDL-c,
methylation of CpG 9 (cg06750524) had a significantly positive
association (P = 0.01).
Based on the observed mutual associations among APOE methylation
patterns, age, and plasma lipids, we proposed that the effect of age on
blood lipids may partially contributed by the changes in APOE methyl-
ation patterns. To test this hypothesis, we first conducted a qualitative
analysis by plotting the regression coefficients representing the effects of
age on methylation of each CpG site (Fig. 2A) and the regression
coefficients representing the effects of methylation of each CpG site on
TC (Fig. 2B). The pattern of the association between age and methyl-
ation is moderately parallel to that between methylation and TC, which
showed the negative associations for CpG sites in both Group 1 and
Group 3, both of which demonstrated hypermethylation, and a positive
association for CpG sites in Group 2 which showed hypomethylation.
Next, we performed a quantitative analysis to test whether APOE
methylation patterns are the intermediate factor between age and TC.
We found that regression coefficients of the effect of age on TC became
smaller after the regression model included the adjustment for meth-
ylation levels of almost all the CpG sites except for site 3 (cg01032398).
Also, the likelihood ratio test showed that three CpG sites play a
statistically significant role as the intermediate factor between age and
TC, which were CpG 4 (cg26190885) (P < 0.0001), CpG 10
(cg16471933) (P = 0.04), and CpG 13 (cg21879725) (P = 0.03).
APOE methylation patterns are associated with APOE genetic
variants
We next explored relationships between APOE methylation and APOE
sequence variants. Two CpG sites in Group 2 and Group 3 were
significantly associated with APOE e variants (Table 5). For CpG 9
(cg06750524) and CpG 10 (cg16471933), the order for the methylation
Table 2 Correlations between APOE methylation and APOE gene expression in
ENCODE




Group 1 CpG 1 cg14123992 0.45 0.07
CpG 2 cg04406254 0.66 0.004
CpG 3 cg01032398 0.62 0.008
Group 2 CpG 4 cg26190885 0.17 0.52
CpG 5 cg12049787 0.33 0.20
CpG 6 cg08955609 0.16 0.53
CpG 7 cg18768621 0.48 0.05
CpG 8 cg19514613 0.40 0.11
CpG 9 cg06750524 0.28 0.28
Group 3 CpG 10 cg16471933 0.39 0.12
CpG 11 cg05501958 0.21 0.43
CpG 12 cg18799241 0.51 0.04
CpG 13 cg21879725 0.30 0.25
*CpG groups were defined according to both the methylation level and region of
the gene.
Table 3 APOE methylation patterns and plasma lipids by age quintiles in GOLDN*
Outcomes
CpG
group CpG # CpG name
Age quintiles†
P‡
Q1 Q2 Q3 Q4 Q5
24 (18–34) years 40 (35–43) years 47 (44–51) years 57 (52–64) years 71 (65–87) years
n = 200 n = 185 n = 204 n = 209 n = 195
APOE methylation
(%)
Group 1 CpG 1 cg14123992 88.13 (0.45) 85.32 (0.83) 86.07 (0.61) 85.72 (0.42) 84.46 (0.62) 8.00E-05
CpG 2 cg04406254 72.36 (0.24) 70.62 (0.35) 70.75 (0.33) 70.29 (0.34) 69.90 (0.27) 2.06E-08
CpG 3 cg01032398 82.80 (0.18) 81.58 (0.45) 82.22 (0.22) 81.96 (0.23) 81.39 (0.23) 1.16E-04
Group 2 CpG 4 cg26190885 9.17 (0.10) 9.30 (0.09) 9.32 (0.08) 9.44 (0.08) 9.33 (0.08) 0.11
CpG 5 cg12049787 6.63 (0.24) 7.13 (0.42) 6.94 (0.35) 6.80 (0.19) 7.02 (0.23) 0.44
CpG 6 cg08955609 3.79 (0.11) 5.38 (0.77) 4.83 (0.59) 4.69 (0.44) 4.69 (0.42) 0.19
CpG 7 cg18768621 11.39 (0.86) 14.77 (1.23) 11.98 (0.81) 12.76 (1.12) 13.70 (1.10) 0.30
CpG 8 cg19514613 13.13 (0.15) 13.21 (0.22) 13.40 (0.15) 13.92 (0.20) 13.61 (0.18) 0.004
CpG 9 cg06750524 24.78 (0.25) 25.75 (0.51) 25.51 (0.42) 25.35 (0.35) 24.66 (0.27) 0.60
Group 3 CpG 10 cg16471933 80.97 (0.35) 79.51 (0.49) 80.01 (0.50) 80.28 (0.37) 79.54 (0.39) 0.04
CpG 11 cg05501958 96.29 (0.11) 95.17 (0.60) 95.41 (0.50) 95.65 (0.37) 95.98 (0.09) 0.62
CpG 12 cg18799241 87.27 (0.87) 83.57 (1.27) 86.23 (0.86) 86.49 (1.08) 85.62 (1.08) 0.68
CpG 13 cg21879725 84.22 (1.15) 80.46 (1.37) 83.64 (1.02) 83.74 (1.20) 82.12 (1.24) 0.62
Plasma lipids TC (mg dL1) 164.10 (2.81) 186.92 (2.37) 191.59 (2.21) 198.47 (2.57) 188.96 (2.87) 1.04E-07
LDL-c (mg dL1) 104.09 (2.57) 120.23 (2.20) 121.90 (1.91) 127.20 (2.20) 116.65 (2.32) 2.00E-04
HDL-c (mg dL1) 46.32 (0.90) 48.58 (0.85) 48.63 (0.90) 48.74 (0.94) 49.63 (0.95) 0.01
TG (mg dL1) 87.02 (1.05) 105.94 (1.05) 114.35 (1.05) 132.17 (1.04) 127.43 (1.05) 1.94E-08
*Data are the least square means (standard error of the means) of outcomes adjusted for the covariates below;
†Median age (minimum age–maximum age) within each quintile were presented;
‡P: P-value for the association of age (quintile) with APOE methylation patterns and plasma lipids, adjusting for pedigree, sex, center, and the first principal component of
cellular purity and population structure.
Age and genetic variants for APOE methylation, Y. Ma et al.52
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
level is e2 carriers < e3/e3 < e4 carriers (P = 3.51E-05 and 0.03, respec-
tively). TwootherCpG sites hada borderline significance (P = 0.05),which
were CpG 8 (cg19514613) and CpG 13 (cg21879725).
Promoter SNP rs405509 had significant associations with methylation
of CpG 2 (cg04406254) in Group 1, CpG 9 (cg06750524) in Group 2,
and CpG 10 in Group 3 (cg16471933) (P = 0.02, 0.03, and 0.01,
respectively) (Table 5). Homozygotes of the minor allele (AA) had the
highest methylation levels for these three CpG sites, while the
homozygotes of major allele (CC) had the lowest, with the values for
the heterozygotes in the middle.
APOEmethylation patterns are modulated by the interactions
between age and APOE genetic variants
Finally, we examined genetic variants as potential modulators of the
effect of age on APOE methylation. Promoter SNP rs405509 signif-
icantly interacted with age to modulate methylation of CpG 3
(cg01032398) (P for interaction = 0.03), a CpG site in Group 1
(Fig. 3). For major allele carriers (CC and AC), older age was
significantly associated with lower methylation of CpG 3 (P for
trend = 0.01 and 0.004, respectively). However, there was no associ-
ation between age and methylation of CpG 3 in homozygotes for the
minor allele (AA) (P for trend = 0.97).
Discussion
In the current study, we described the methylation patterns of the APOE
locus and their correlations with gene expression and observed
associations between APOE methylation and age, blood lipids, and
sequence variants, as well as an interaction between age and a
methylation-associated promoter variant. This is the first study to explore
APOE methylation at single nucleotide resolution in a population of
almost a thousand individuals.
Our finding that age is associated with APOEmethylation is consistent
with a previous study by Wang et.al. (Wang et al., 2008), showing that
the differences in APOE methylation between individuals with and
without Alzheimer’s disease increases with age. Other studies demon-
strated that age affects global DNA methylation (Fraga et al., 2005).
Compared to younger monozygous twins, older twins exhibited greater
differences in DNA methylation. This may be a consequence of the fact
that DNA methylation is modifiable by environmental factors (Cedar &
Bergman, 2012), which accumulate gradually or change continuously
with age. In our study, we expected APOE methylation to change with
age because APOE is considered an age-related gene. This is based on
the genetic associations between APOE variants and many age-related
diseases, such as coronary heart disease (Ward et al., 2009), athero-
sclerosis (Davignon et al., 1988), age-related macular degeneration
(AMD) (Klaver et al., 1998), and Alzheimer’s disease (Saunders et al.,
1996). We also observed that the direction of the age-associated
differences in methylation levels appeared to be associated with the
existing degree of methylation. Specifically, we observed that greater
age was associated with less methylation in hypermethylated regions but
with greater methylation in hypomethylated regions. Finally, we
obtained both qualitative and quantitative evidence to support the
potential biological connections between age, APOE methylation, and
plasma lipids by indicating that the effects of age on plasma lipids may
partially act through APOE methylation. However, the magnitude of the
effect of APOE methylation is small, which may be related to the tiny
contribution of the single APOE gene to the entire genome-wide effects
of the age on DNA methylation.
Two hypothetical mechanisms for the observed differences in APOE
methylation by APOE variants are differential allelic gene expression and
changes in the DNA sequence that affect CpG site formation. With
respect to the first mechanism, the minor A allele of the promoter SNP
rs405509 has been reported to exhibit lower gene transcription
compared to the major C allele (Artiga et al., 1998). For the APOE e
variants, mRNA expression for e3 allele was shown to be greater than
that of e4 (Lambert et al., 1997). Based on the established relationship
between DNA methylation and reduced gene expression (Lindahl, 1981),
our findings of higher methylation levels for carriers of the rs405509 A
allele and e4 allele in GOLDN are consistent with the lower expression
reported in previous studies. The second potential mechanism by which
genotype may alter methylation is based on the creation and disruption
of CpG sites by nucleotide changes that determine the APOE e variants.
Table 4 Associations between APOE methylation patterns and plasma lipids in GOLDN
CpG group CpG # CpG name
TC LDL-c HDL-c TG (log)
Coefficient* SEM* P† Coefficient* SEM* P† Coefficient* SEM* P† Coefficient‡ SEM‡ P†
Group 1 CpG 1 cg14123992 0.32 0.10 3.53E03 0.20 0.11 0.07 0.10 0.05 0.08 0.001 0.002 0.53
CpG 2 cg04406254 0.56 0.20 0.02 0.34 0.18 0.10 0.08 0.08 0.38 0.01 0.005 0.09
CpG 3 cg01032398 0.12 0.23 0.61 0.05 0.20 0.81 0.14 0.08 0.24 0.001 0.01 0.87
Group 2 CpG 4 cg26190885 0.37 0.89 0.67 0.25 0.75 0.74 0.29 0.31 0.35 0.01 0.01 0.72
CpG 5 cg12049787 0.36 0.20 0.06 0.24 0.21 0.25 0.15 0.12 0.24 0.002 0.004 0.63
CpG 6 cg08955609 0.14 0.13 0.30 0.16 0.13 0.26 0.03 0.04 0.45 0.001 0.003 0.68
CpG 7 cg18768621 0.20 0.08 0.02 0.13 0.07 0.07 0.01 0.03 0.63 0.003 0.001 0.06
CpG 8 cg19514613 0.30 0.43 0.50 0.07 0.38 0.86 0.12 0.16 0.44 0.002 0.01 0.77
CpG 9 cg06750524 0.35 0.17 0.06 0.45 0.15 0.01 0.02 0.06 0.70 0.001 0.00 0.74
Group 3 CpG 10 cg16471933 0.49 0.15 0.01 0.24 0.14 0.11 0.01 0.07 0.93 0.01 0.004 0.08
CpG 11 cg05501958 0.28 0.12 0.09 0.29 0.11 0.09 0.04 0.05 0.39 7.70E05 0.003 0.98
CpG 12 cg18799241 0.19 0.07 0.02 0.11 0.06 0.12 0.01 0.03 0.76 0.002 0.002 0.19
CpG 13 cg21879725 0.19 0.06 0.008 0.11 0.06 0.06 0.004 0.02 0.86 0.002 0.001 0.06
*Coefficient and SEM represent changes in plasma lipids (mg dL1) corresponding to 1% increase in DNA methylation adjusing for the covariates below.
†P: P-value for the association between DNA methylation (%) and plasma lipids adjusting for pedigree, sex, center, and the first principal component of cellular purity and
population structure.
‡Coefficient and SEM represent changes in log-transformed TG (mg dL1) corresponding to 1% increase in DNA methylation adjusing for the covariates below.
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The two SNPs that constitute APOE e variants are both CpG-related
SNPs. That means that individuals with e3/e3 genotype have 2 CpG sites
created by the homozygous C alleles for rs7412, e2 carriers have either 0
or 1 CpG site created by the heterozygous C allele for rs7412, and e4
carriers have either 3 or 4 CpG sites created by the homozygous C alleles
of rs7412 and the heterozygous or the homozygous C alleles of
rs429358. Based on the recognition that most DNA methylation in the
mammalian genome occurs on CpG sites (Lister et al., 2009), the density
Table 5 APOE methylation patterns by genetic variants in GOLDN*
CpG group CpG # CpG name
APOE rs405509 APOE e variants
CC AC AA
P†
e2 carriers e3/ e3 e4 carriers
P†n = 256 n = 500 n = 236 n = 99 n = 588 n = 257
Group 1 CpG 1 cg14123992 85.87 (0.56) 86.19 (0.35) 85.52 (0.62) 0.61 86.84 (0.32) 85.70 (0.41) 86.14 (0.49) 0.84
CpG 2 cg04406254 69.96 (0.37) 71.07 (0.18) 71.10 (0.26) 0.02 70.36 (0.34) 70.84 (0.20) 70.85 (0.30) 0.42
CpG 3 cg01032398 81.80 (0.19) 81.98 (0.22) 82.23 (0.21) 0.19 82.07 (0.30) 81.78 (0.19) 82.43 (0.21) 0.07
Group 2 CpG 4 cg26190885 9.22 (0.08) 9.34 (0.05) 9.35 (0.08) 0.23 9.28 (0.11) 9.38 (0.05) 9.23 (0.07) 0.29
CpG 5 cg12049787 6.97 (0.30) 6.87 (0.18) 6.89 (0.28) 0.85 6.57 (0.12) 7.01 (0.18) 6.83 (0.28) 0.87
CpG 6 cg08955609 5.11 (0.57) 4.61 (0.31) 4.31 (0.38) 0.26 4.00 (0.08) 4.80 (0.32) 4.69 (0.47) 0.55
CpG 7 cg18768621 13.45 (0.99) 13.05 (0.60) 11.93 (0.74) 0.24 13.56 (1.87) 13.37 (0.60) 11.51 (0.59) 0.11
CpG 8 cg19514613 13.20 (0.17) 13.52 (0.11) 13.61 (0.14) 0.06 13.17 (0.29) 13.37 (0.11) 13.72 (0.13) 0.05
CpG 9 cg06750524 24.41 (0.38) 25.52 (0.21) 25.44 (0.26) 0.03 23.85 (0.29) 25.05 (0.19) 26.25 (0.33) 3.51E-05
Group 3 CpG 10 cg16471933 79.53 (0.37) 80.02 (0.28) 80.78 (0.30) 0.01 79.07 (0.57) 80.07 (0.26) 80.46 (0.29) 0.03
CpG 11 cg05501958 95.28 (0.49) 95.71 (0.24) 96.15 (0.10) 0.09 96.15 (0.11) 95.67 (0.24) 95.58 (0.38) 0.41
CpG 12 cg18799241 85.34 (0.99) 85.69 (0.62) 86.84 (0.74) 0.24 85.15 (1.80) 85.45 (0.61) 87.06 (0.58) 0.13
CpG 13 cg21879725 82.35 (1.12) 82.41 (0.72) 84.45 (0.82) 0.14 81.57 (2.16) 82.21 (0.72) 84.68 (0.66) 0.05
*Data are the least square means (standard error of the means) of APOE methylation (%) adjusted for the covariates below.
†P: P-value for the association between APOE methylation (%) and genetic variants adjusting for pedigree, sex, center, and the first principal components of cellular purity
and population structure.
Fig. 3 Interaction between rs405509 and age for methylation of CpG 3 (cg01032398) in GOLDN. Predicted methylation levels of cg01032398 were calculated based on the
regression coefficient of the exposure variable (age) for the outcome (methylation) with the adjustment for the covariates of pedigree, sex, center, and the first principle
component of cellular purity and population structure. Predicted methylation levels of cg01032398 by genotype of rs405509 were plotted against age, adjusted for
pedigree, gender, center, and the first principal component of cellular purity and population structure. P-values indicate the statistical significance of the adjusted interaction
term and adjusted regression coefficients in the regression line corresponding to three genotype groups of rs405509 (diamond for CC, square for AC, and triangle for AA).
Fig. 2 APOE methylation patterns may act as the intermediate factors of the effects of age on blood lipids. Panels A and B provided qualitative evidence by listing 13 CpG
sites as x-axis and the y-axis are the regression coeffiecients of age for the outcome of methylation (%) (A) and the regression coefficients of methylation for the outcome of
TC (mg dL1) (B). Black dot represents point estimate of regression coefficient for each CpG site from generalized linear models adjusting for pedigree, gender, study center,
and the first principal component of cellular purity and population structure. Lower and upper bars represent the lower and higher values of 95% confidence intervals for
each coefficient. Black line is the fitted line for the pattern of all 13 CpG sites. Panel C provided quantitative evidence based on the likelihood ratio test of the differences in
the regression coefficients of the effects of age on TC yielded by the model without and with the adjustment of APOE methylation. aCoefficient and SEM, and bP represent
the magnitude and significance of the changes in blood total cholesterol (mg dL1) corresponding to 1 year increase in age adjusting for pedigree, sex, center, and the first
principal component of cellular purity and population structure; cCoefficient and SEM, and dP represent the magnitude and significance of the changes in blood total
cholesterol (mg dL1) corresponding to 1 year increase in age with further adjustment for the methylation levels of each CpG site at APOE locus in addition to pedigree, sex,
center, and the first principal component of cellular purity and population structure.
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of CpG sites is likely to affect the local DNA methylation patterns. The
fact that e4 carriers have the greatest number of CpG sites while e2
carriers have the smallest number with e3/e3 in the middle is consistent
with our finding that methylation levels for most CpG sites are in the
order of e4 carriers > e3/e3 > e2 carriers.
In light of our findings that both age and APOE genotype were
related to methylation, a logical next step was to examine whether
these two factors might act in combination to alter methylation. Our
observation that promoter SNP rs405509 significantly modified the
association between age and promoter methylation is novel and
plausible. Greater age was associated with less promoter methylation
in the carriers of the major allele (CC and AC) but not in the
homozygotes of the minor allele (AA), such that methylation of those
in the AA group remained high regardless of age. This age-related
allelic difference in methylation level may provide mechanistic support
for previous findings linking the A allele of rs405509 to greater risk of
myocardial infarction (Lambert et al., 2000), premature coronary heart
disease (Viitanen et al., 2001), and Alzheimer’s disease (Lambert
et al., 1998), but lower plasma concentration of ApoE (Lambert et al.,
2000).
This study had a number of limitations. Based on the cross-sectional
study design, we cannot establish causality. Further mechanistic studies
are necessary. The measurement of APOE methylation in circulating
CD4+ T lymphocytes may provide a limited perspective on a protein with
multiple functions. However, the observed consistent methylation
patterns across different cell types increases the generalizability of our
findings. Also, measurements of APOE in circulating cells may not
provide direct evidence for age-related diseases, but circulating APOE
could provide indirect evidence through their demonstrated effects on
plasma lipids. In addition, circulating APOEmay act as a biomarker of the
changes in the neuronal systems based on our findings of the highly
similar methylation patterns between blood T lymphocytes and brain
tissues. Finally, the selected 13 CpG sites may not represent the
methylation pattern of the whole APOE, but the usual highly correlated
methylation status of the nearby CpG sites (Shoemaker et al., 2010) and
the consistent methylation patterns between our observation and
previous publication with higher coverage may ameliorate this limitation
to some extent.
In summary, we characterized thirteen CpG sites at the APOE locus
into three groups based on their genetic locations and methylation status
measured in both primary T cells in GOLDN and a wide array of other cell
types obtained through ENCODE and previous publications and observed
that most of these sites were negatively correlated with APOE gene
expression based on ENCODE data. With a large population in GOLDN,
we found that age was indeed associated with APOE methylation and
linked those associations to changes in plasma lipid profile. Furthermore,
we observed that methylation-associated genetic variants of APOE
modified the aging effect on methylation. Our findings are novel and
consistent with the previous evidence from genetic studies and may




The GOLDN study was designed to evaluate genetic factors that
modulate plasma lipid responses to a diet intervention (consumption
of a high-fat meal) and fenofibrate treatment. GOLDN participants are
of European ancestry and were enrolled from the National Heart,
Lung, and Blood Institute Family Heart Study (Higgins et al., 1996).
This GOLDN analysis included 475 men and 518 women (age ranged
from 18 to 87 years) who have baseline data for all required variables.
The detailed design and methodology of GOLDN has been described
(Corella et al., 2007). Of relevance for this analysis, GOLDN required
all subjects with a history of antilipemic drug use to be off all
antilipemic medications for at least 4 weeks prior to their study visit.
The protocol for this study was approved by the Human Studies
Committee of Institutional Review Board at the University of Minne-
sota, University of Utah, and Tufts University/New England Medical
Center. Written informed consent was obtained from all participants.
Fasting blood samples were collected to measure the lipid profile, and
detailed methodology was described previously (Tsai et al., 2005).
Dietary intake was estimated using the diet history questionnaire
(Subar et al., 2001; Thompson et al., 2002). Physical activity was
assessed by a questionnaire containing questions on the number of
hours per day dedicated to different levels (heavy, slight, and
sedentary) of activity (Corella et al., 2011).
Genotyping and methylation measurements
Genomic DNA for sequence genotyping was extracted from blood
samples using Gentra Puregene Blood Kits (Gentra Systems, Inc.,
Minneapolis, MN, USA). Genotypes of 3 SNPs included in the current
study, which were rs405509, rs429358, and rs7412, were obtained
using TaqMan assays on a ABI 7900HT system (Applied Biosystems,
Foster City, CA, USA). APOE genotypes were called on the basis of the
guidelines of Hixson and Vernier (Hixson & Vernier, 1990) according to
the genotypes of rs429358 and rs7412.
Detailed methodology to measure DNA methylation was described
previously (Absher et al., 2013). CD4+ T cells for methylation
measurement were extracted from baseline frozen buffy coat samples
isolated from peripheral blood using positive selection (Invitrogen,
Grand Island, NY, USA) followed by sorting of subsets by flow
cytometry (FACSAriaII, BD Biosciences, San Jose, CA, USA). Cells were
then lysed, and DNA was extracted using QIAGEN DNAeasy kits
(QIAGEN, Germantown, MD, USA). DNA sample (500 ng) was treated
with sodium bisulfite using Zymo EZ DNA methylation kit (Zymo
Research Corporation, Irvine, CA, USA). DNA methylation was
measured by the Infinium Human Methylation 450K BeadChip
(Illumina, San Diego, CA, USA) through amplification, hybridization,
and imaging steps. Intensity files were generated and analyzed with
Illumina’s GenomeStudio, through which beta scores and ‘detection
P-values’ were generated. These beta scores represent the proportion
of total signal from the methylation-specific probe or color channel.
The ‘detection P-values’ were defined as the probability that the total
intensity for a given probe falls within the background signal intensity.
Those CpG probes with ‘detection P-values’ greater than 0.01 and
with more than 10% of samples that failed to yield adequate intensity
were eliminated from further analysis. Those samples with more than
1.5% missing data points across ~470,000 autosomal CpGs were
removed. After quality control, 13 CpG sites related to APOE
remained. Starting from the 50, the first four CpG sites
(cg14123992, cg04406254, cg01032398, and cg26190885) were
located within 1.5 kb before the transcription start site, the fifth CpG
site (cg12049787) was within the first exon, the next three CpG sites
(cg08955609, cg18768621, and cg19514613) were within the first
intron, the ninth CpG site (cg06750524) was within the second
intron, and the last four CpG sites (cg16471933, cg05501958,
cg18799241, and cg21879725) were within the fourth exon.
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DNA methylation datasets
Methylation levels of all 13 CpG sites for 61 cell lines and one primary
liver cell in ENCODE were downloaded (September 20, 2013) from UCSC
genome browser HAIB Methyl450 track (http://hgdownload.cse.ucsc.
edu/goldenPath/hg19/encodeDCC/wgEncodeHaibMethyl450/) and rep-
resented by a heat map using R packages of ‘gplots’ (http://cran.
r-project.org/web/packages/gplots/index.html) and ‘RColorBrewer’
(http://cran.r-project.org/web/packages/RColorBrewer/index.html). The
score of the methylation value associated with each CpG site was
defined as the beta value multiplied by 1000, with the beta value in turn
defined as the proportion of the intensity value from the methylated
bead type from the sum of the intensity values from both methylated
and unmethylated bead type plus 100.
Published methylation data of primary cells from tissues of brain (Day
et al., 2013; Kozlenkov et al., 2014; Wockner et al., 2014), muscle
(Ribel-Madsen et al., 2012; Day et al., 2013; Zykovich et al., 2013), fat
(Ribel-Madsen et al., 2012; Grundberg et al., 2013), and saliva (Liu
et al., 2010; Bocklandt et al., 2011; Souren et al., 2013; Park et al.,
2014) were obtained through Gene Expression Omnibus (GEO) (http://
www.ncbi.nlm.nih.gov/geo/) (Edgar et al., 2002) and ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) (Rustici et al., 2012).
Gene expression in ENCODE
Gene expression data for APOE in 17 cell lines, which also had
methylation data available, in ENCODE were downloaded (11-08-2013)
from UCSC genome browser Duke Affymetrix Exon Array track (http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeDukeAffyExon/). This track displayed exon array data that had
been aggregated to the gene level for those probes that had been linked
to genes. The expression score for each cell line represented a linearly
scaled value for that particular cell type multiplied by 100 and ranged
from 0 to 1000.
Statistical methods
In ENCODE data, Pearson’s correlation analysis was conducted to test
the correlations between methylation of each CpG site and gene
expression of APOE. In GOLDN, Mantel–Haenszel v2 tests and ANOVA
tests were used to examine the trend of significance in characteristics of
the study population, as categorical and continuous variables, respec-
tively, by age, categorized in quintiles. Generalized linear models were
used to test the association of methylation of each CpG site with age
(continuous variable), blood lipids, and APOE genotypes, and the
interaction between age (continuous variable) and selected variants.
Each CpG site was included into the model separately. APOE e variants
were coded into three categories, e3/e3, e2 carriers (including e2/e2 and
e2/e3), and e4 carriers (including e4/e4 and e3/e4). Individuals with the
e2/ e4 genotype (n = 46) were excluded from the analysis to distinguish
the distinct role of each variant. The primary analysis was adjusted for
pedigree, sex, study center, and the first principal component of both
cellular purity (Frazier-Wood et al., 2014) and population structure. To
test the effect of other potential confounders, the secondary analysis
was adjusted for smoking (never smoker, past smoker, and current
smoker), drinking (ever drink alcohol or not), total energy intake
(kcal day1), physical activity (hours of total physical activity day1),
vitamin B12 intake (lg day1), folate intake (lg day1), hormone
replacement therapy in women, a history of taking antilipemic medica-
tion, and time of fasting blood drawn (am or pm) (Reddy & Reddy, 1990;
Armstrong et al., 2013). Likelihood ratio tests were conducted to
analyze whether the effects of age on plasma TC is partially through
methylation of APOE. Each continuous variable was tested for normality,
and log-transformations were performed for those variables not
following a normal distribution. Correlation analysis with data from
ENCODE consortium and all data analysis with GOLDN population were
performed using SAS (version 9.3 for Windows; SAS Institute, Inc. Cary,
NC, USA). Considering the main hypothesis is the general pattern of
APOE methylation rather than the specific CpG site, a two-tailed P-value
of < 0.05 was considered statistically significant.
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Supporting Information
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article at the publisher’s web-site.
Table S1 Cell types and tissues included in the current study.
Fig. S1 Heat map of APOE methylation patterns measured in the blood T
lymphocyte in GOLDN. The pink represents hypermethylation (> 50%), the
green represents hypomethylation (< 50%), and the gray represents missing
value.
Fig. S2 Heat map of APOE methylation patterns measured in the
primary brain tissue. The pink represents hypermethylation (> 50%), the
green represents hypomethylation (< 50%), and the gray represents missing
value.
Fig. S3 Heat map of APOE methylation patterns measured in the primary
saliva tissue. The pink represents hypermethylation (> 50%), the green
represents hypomethylation (< 50%), and the gray represents missing value.
Fig. S4 Heat map of APOE methylation patterns measured in the primary
adipose tissue. The pink represents hypermethylation (> 50%), the green
represents hypomethylation (< 50%), and the gray represents missing value.
Fig. S5 Heat map of APOE methylation patterns measured in the primary
muscle. The pink represents hypermethylation (> 50%), the green represents
hypomethylation (< 50%), and the gray represents missing value.
Fig. S6 Heat map of APOE methylation patterns measured in primary
hepatocyte and 61 cell lines in ENCODE. The pink represents hypermethy-
lation (> 50%), the green represents hypomethylation (< 50%), and the gray
represents missing value.
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